Pfizer (NYSE:PFE) Trading Down 2% - Should You Sell?

Key Points

• Pfizer's stock has decreased by 2%, trading between $23.58 and $23.61 on Thursday, with an increased trading volume of approximately 56.5 million shares.
• Equity analysts have set various price targets for Pfizer, with notable adjustments including a downgrade from Berenberg Bank from $28.00 to $25.00 and an upgrade from Wall Street Zen to a buy rating.
• The company reported earnings of $0.78 per share for the last quarter, significantly exceeding analysts' expectations, and it projects fiscal year 2025 EPS guidance between 2.900 and 3.100.

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price was down 2% during trading on Thursday . The stock traded as low as $23.58 and last traded at $23.61. Approximately 56,478,639 shares changed hands during trading, an increase of 24% from the average daily volume of 45,386,762 shares. The stock had previously closed at $24.09.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PFE shares. Berenberg Bank lowered their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, September 20th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Trading Down 2.0%

The stock has a market cap of $134.25 billion, a price-to-earnings ratio of 12.56, a PEG ratio of 0.85 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business's 50 day simple moving average is $24.59 and its 200 day simple moving average is $24.18.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm earned $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Institutional Trading of Pfizer

Hedge funds have recently modified their holdings of the stock. Capital Advisory Group Advisory Services LLC raised its stake in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares in the last quarter. Citizens National Bank Trust Department grew its position in Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock worth $1,118,000 after purchasing an additional 395 shares in the last quarter. Peak Asset Management LLC lifted its stake in Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock worth $697,000 after acquiring an additional 402 shares in the last quarter. Able Wealth Management LLC boosted its position in Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock worth $512,000 after acquiring an additional 413 shares during the period. Finally, Trust Co of the South grew its stake in Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.